GZ1

GZ1 is an experimental monoclonal antibody targeting **CD36** (also known as cluster of differentiation 36 or fatty acid translocase), a scavenger receptor involved in lipid uptake and metabolic signaling. In the treatment of **acute myeloid leukemia (AML)**, CD36 upregulation is associated with metabolic adaptation, chemotherapy resistance (particularly to cytarabine), and poor clinical prognosis. GZ1 binds to CD36 on leukemia cells, inhibiting its function and sensitizing the cells to chemotherapeutic agents. The therapeutic efficacy of GZ1 is highly dependent on its **Fc-mediated effector functions**, such as antibody-dependent cellular cytotoxicity (ADCC) or phagocytosis (ADCP), with IgG1 and IgG2a isotypes demonstrating superior synergistic effects compared to IgG3. Preclinical studies have shown that GZ1, especially when combined with cytarabine (Ara-C), significantly reduces tumor burden and extends survival in AML models.

Other names

anti-CD36 mAbanti-CD-36 mAbanti-CD 36 mAbanti-CD36 monoclonal antibodyanti-CD-36 monoclonal antibodyanti-CD 36 monoclonal antibodyCD36 monoclonal antibodyCD-36 monoclonal antibodyCD 36 monoclonal antibody